ATE489096T1 - Pharmazeutische magensaftresistent überzogene zusammensetzung enthaltend prostaglandin-analoga als chloridkanalöffner - Google Patents

Pharmazeutische magensaftresistent überzogene zusammensetzung enthaltend prostaglandin-analoga als chloridkanalöffner

Info

Publication number
ATE489096T1
ATE489096T1 AT04747335T AT04747335T ATE489096T1 AT E489096 T1 ATE489096 T1 AT E489096T1 AT 04747335 T AT04747335 T AT 04747335T AT 04747335 T AT04747335 T AT 04747335T AT E489096 T1 ATE489096 T1 AT E489096T1
Authority
AT
Austria
Prior art keywords
entericial
analogas
pharmaceutical
chloride channel
channel opener
Prior art date
Application number
AT04747335T
Other languages
English (en)
Inventor
Ryuji Ueno
Original Assignee
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sucampo Ag filed Critical Sucampo Ag
Application granted granted Critical
Publication of ATE489096T1 publication Critical patent/ATE489096T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT04747335T 2003-07-03 2004-07-05 Pharmazeutische magensaftresistent überzogene zusammensetzung enthaltend prostaglandin-analoga als chloridkanalöffner ATE489096T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48430403P 2003-07-03 2003-07-03
PCT/JP2004/009867 WO2005002588A1 (en) 2003-07-03 2004-07-05 Enteric coated composition comprising prostaglandin analogs as chloride channel opener

Publications (1)

Publication Number Publication Date
ATE489096T1 true ATE489096T1 (de) 2010-12-15

Family

ID=33563976

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04747335T ATE489096T1 (de) 2003-07-03 2004-07-05 Pharmazeutische magensaftresistent überzogene zusammensetzung enthaltend prostaglandin-analoga als chloridkanalöffner

Country Status (6)

Country Link
US (1) US8337891B2 (de)
EP (1) EP1641462B1 (de)
JP (1) JP5294559B2 (de)
AT (1) ATE489096T1 (de)
DE (1) DE602004030245D1 (de)
WO (1) WO2005002588A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1562604T3 (da) * 2002-10-23 2012-04-02 Sucampo Ag Prostaglandinforbindelser til behandling af fedme
ATE489096T1 (de) * 2003-07-03 2010-12-15 Sucampo Ag Pharmazeutische magensaftresistent überzogene zusammensetzung enthaltend prostaglandin-analoga als chloridkanalöffner
TWI387454B (zh) 2004-09-02 2013-03-01 蘇坎波公司 治療胃腸道疾病之方法及組成物
CA2637274C (en) * 2006-01-24 2013-06-04 R-Tech Ueno, Ltd. Soft-gelatin capsule formulation
EP1984027B1 (de) 2006-01-24 2015-12-30 R-Tech Ueno, Ltd. Pharmazeutische zusammensetzung mit einer bizyklischen verbindung sowie verfahren zur stabilisierung der bicyclischen verbindung
CA2642744C (en) * 2006-02-28 2015-02-24 Sucampo Ag Method and composition for treating chronic obstructive pulmonary disease
WO2009104205A1 (en) * 2008-02-20 2009-08-27 Lupin Limited Delayed release formulation of chloride channel activator
US20110034424A1 (en) * 2009-06-30 2011-02-10 Sucampo Ag Method for the long term nsaid use
JP2011032262A (ja) * 2009-06-30 2011-02-17 Sucampo Ag Ｎｓａｉｄの長期使用のための医薬組成物
US20120232043A1 (en) * 2009-09-15 2012-09-13 Cemag Lubiprostone for obstetrical or gynecological applications
US9084815B2 (en) * 2009-09-16 2015-07-21 Sucampo Ag Method for treating damage induced by an anti-tumor agent, treating mucositis and treating tumor
WO2014007606A1 (en) 2012-07-05 2014-01-09 N.V. Nutricia Product for use in the prophylactic or therapeutic treatment of a negative emotion or introvert behaviour
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
KR20180058758A (ko) 2015-09-22 2018-06-01 그레이버그 비젼, 인크. 안구 장애의 치료를 위한 화합물 및 조성물

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU519132B2 (en) * 1978-01-31 1981-11-12 Kureha Kagaku Kogyo K.K. Prostaglandin-steroid conjugates
DE3041601A1 (de) * 1980-10-31 1982-06-16 Schering Ag, 1000 Berlin Und 4619 Bergkamen Neue prostacyclinderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
JPS59155325A (ja) 1983-02-25 1984-09-04 Kohjin Co Ltd 水系の腸溶性コ−テイング剤の製法
DE3504044A1 (de) * 1985-02-04 1986-08-07 Schering AG, Berlin und Bergkamen, 1000 Berlin 9-halogenprostaglandin-clathrate und ihre verwendung als arzneimittel
US5166174A (en) 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
CA1322749C (en) 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
US5221763A (en) 1987-04-30 1993-06-22 R-Tech Ueno, Ltd. Prostaglandins of the F series
TW224942B (de) 1990-04-04 1994-06-11 Adka Ueno Kk
JPH05139964A (ja) 1991-11-14 1993-06-08 Takada Seiyaku Kk 塩酸メキシレチン腸溶性製剤
CA2150287C (en) 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
JP3187438B2 (ja) 1996-06-10 2001-07-11 株式会社アールテック・ウエノ エンドセリン拮抗剤
GB9614902D0 (en) 1996-07-16 1996-09-04 Rhodes John Sustained release composition
ATE221048T1 (de) * 1996-09-17 2002-08-15 Asahi Glass Co Ltd Fluorierte prostaglandinderivate und medikamente
NZ336362A (en) 1997-10-13 2001-01-26 R Tech Ueno Ltd Use of a 15-keto-prostaglandin compound as a portal hypertension inhibitor
JP2000319166A (ja) 1999-03-10 2000-11-21 Kyowa Hakko Kogyo Co Ltd 腸溶製剤
US6197329B1 (en) * 1999-05-03 2001-03-06 Drugtech Corporation Anti-nausea compositions and methods
RU2695274C3 (ru) * 1999-10-15 2020-11-09 Сукампо Аг Новые композиции и способы их стабилизации
US6414016B1 (en) * 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
EP1420794B1 (de) 2001-08-31 2017-12-27 Sucampo AG Prostaglandin-analoga als chloridkanalöffner
AR037524A1 (es) * 2001-11-14 2004-11-17 Sucampo Ag Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion
TWI263505B (en) 2001-11-19 2006-10-11 Sucampo Ag Pharmaceutical composition comprising a C1C-2 channel opener
DK1562604T3 (da) 2002-10-23 2012-04-02 Sucampo Ag Prostaglandinforbindelser til behandling af fedme
BRPI0317740B8 (pt) * 2002-12-27 2021-05-25 Sucampo Ag uso do composto 13,14-diidro-15-ceto-16,16-diflúorprostaglandina e1
ATE489096T1 (de) * 2003-07-03 2010-12-15 Sucampo Ag Pharmazeutische magensaftresistent überzogene zusammensetzung enthaltend prostaglandin-analoga als chloridkanalöffner
TWI387454B (zh) * 2004-09-02 2013-03-01 蘇坎波公司 治療胃腸道疾病之方法及組成物

Also Published As

Publication number Publication date
EP1641462A1 (de) 2006-04-05
US8337891B2 (en) 2012-12-25
JP5294559B2 (ja) 2013-09-18
JP2007518674A (ja) 2007-07-12
EP1641462B1 (de) 2010-11-24
WO2005002588A1 (en) 2005-01-13
DE602004030245D1 (de) 2011-01-05
US20060240106A1 (en) 2006-10-26

Similar Documents

Publication Publication Date Title
ATE489096T1 (de) Pharmazeutische magensaftresistent überzogene zusammensetzung enthaltend prostaglandin-analoga als chloridkanalöffner
EA200600620A1 (ru) Набор для ингаляции с ингаляционным порошком, содержащим тиотропий
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
DK1663206T3 (da) 1-(2,3-dimethyl-phenyl)-ethyl-1,3-dihydro-imizadol-2-thion som ikke-sedativ alpha 2A-agonist
NO20074295L (no) Substituerte gamma lactamer som terapeutiske midler
DE60030741D1 (de) Chinazoline verbindungen als heilmittel
CY1113462T1 (el) Μορφη δοσολογιας περιεχουσα παντοπραζολη ως δραστικο συστατικο
ATE356621T1 (de) (s)-2-n-propylamino-5-hydroxytetralin als d3- agonistisches therapeutikum
ATE472529T1 (de) Prolinamidderivate als natriumkanalmodulatoren
EA200500213A1 (ru) Диспергируемые таблетки для орального назначения
BRPI0617655A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, ou um isômero óptico do mesmo, uso de um composto, e, formulação farmacêutica
TW200507838A (en) Active substance combination comprising a 2,5-dihydroxybenzenesulfonic compound and a potassium ion channel modulator
MY142076A (en) Emulsifying systems containing azetidine derivatives
TW200503785A (en) Dosage form containing (S)-pantoprazole as active ingredient
NO20064808L (no) Orale matrixformuleringer med licarbazepin
NO20063293L (no) Farmasoytiske forbindelser
EA200501565A1 (ru) Предназначенная для перорального приёма лекарственная форма для антагонистов протонного насоса
SG144141A1 (en) Semi-solid systems containing azetidine derivatives
EA200801139A1 (ru) Композиция для аэрозольной ингаляции
ITMI20041822A1 (it) "agente terapeutico utile per il trattamento di neoplasie plasmacellulari"
UY27824A1 (es) Nueva formulación para la administración parenteral de crobenetina.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties